Claus Schalper
Vorstandsvorsitzender bei XL-protein GmbH
Profil
Claus Schalper is the founder of Pieris AG and Pieris Pharmaceuticals, Inc., both founded in 2001, where he held the title of Chief Financial Officer.
Mr. Schalper is also the founder of XL-protein GmbH and Anavo Therapeutics BV.
Currently, Mr. Schalper is the Chief Executive Officer at Isarna Therapeutics GmbH since 2021.
Mr. Schalper's former positions include Head-Controlling at Wirecard AG and Principal at Arthur Andersen LLP.
Mr. Schalper received an MBA from the University of Bamberg.
Aktive Positionen von Claus Schalper
Unternehmen | Position | Beginn |
---|---|---|
XL-protein GmbH
XL-protein GmbH Pharmaceuticals: MajorHealth Technology XL-protein GmbH is a German biopharmaceutical company that specializes in the development of long-acting immunosuppressive antibodies for the selective suppression of organ rejection. The private company is based in Freising, Germany and was founded by Claus Schalper, who has been the CEO since incorporation. The company collaborates with other research institutions to develop novel biopharmaceuticals with enhanced action, such as the genetic fusion or chemical coupling of biopharmaceuticals with fully biodegradable PAS sequences. XL-protein's PASylation® technology has demonstrated significantly extended systemic half-life in vivo, potentially offering improved treatment options for autoimmune diseases and cystic fibrosis. | Vorstandsvorsitzender | - |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Vorstandsvorsitzender | 30.09.2021 |
Anavo Therapeutics BV
Anavo Therapeutics BV BiotechnologyHealth Technology Anavo Therapeutics BV is a Dutch company that specializes in developing first-in-class therapeutic programs for several indications in oncology. The company is based in Leiden, Netherlands. The company has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. Anavo is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. Anavo is backed by blue-chip investors m ventures, inkef capital, taiho ventures, mrl ventures fund, and bioqube ventures. The company was founded by Claus Schalper, Birgit Zech, Gerhard Müller. Birgit Zech has been the CEO since incorporation. | Gründer | - |
Ehemalige bekannte Positionen von Claus Schalper
Unternehmen | Position | Ende |
---|---|---|
PIERIS PHARMACEUTICALS, INC. | Gründer | - |
WIRECARD AG | Comptroller/Controller/Auditor | - |
Pieris AG
Pieris AG BiotechnologyHealth Technology Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany. | Gründer | - |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Corporate Officer/Principal | - |
Ausbildung von Claus Schalper
University of Bamberg | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
WIRECARD AG | Finance |
PIERIS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
Pieris AG
Pieris AG BiotechnologyHealth Technology Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany. | Health Technology |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Health Technology |
XL-protein GmbH
XL-protein GmbH Pharmaceuticals: MajorHealth Technology XL-protein GmbH is a German biopharmaceutical company that specializes in the development of long-acting immunosuppressive antibodies for the selective suppression of organ rejection. The private company is based in Freising, Germany and was founded by Claus Schalper, who has been the CEO since incorporation. The company collaborates with other research institutions to develop novel biopharmaceuticals with enhanced action, such as the genetic fusion or chemical coupling of biopharmaceuticals with fully biodegradable PAS sequences. XL-protein's PASylation® technology has demonstrated significantly extended systemic half-life in vivo, potentially offering improved treatment options for autoimmune diseases and cystic fibrosis. | Health Technology |
Anavo Therapeutics BV
Anavo Therapeutics BV BiotechnologyHealth Technology Anavo Therapeutics BV is a Dutch company that specializes in developing first-in-class therapeutic programs for several indications in oncology. The company is based in Leiden, Netherlands. The company has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. Anavo is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. Anavo is backed by blue-chip investors m ventures, inkef capital, taiho ventures, mrl ventures fund, and bioqube ventures. The company was founded by Claus Schalper, Birgit Zech, Gerhard Müller. Birgit Zech has been the CEO since incorporation. | Health Technology |